Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 01I in previously treated stage IV squamous NSCLC
2024-518839-11-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Aug 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised trial in Pulmonary squamous cell carcinoma comparing Ifinatamab deruxtecan, Raludotatug deruxtecan and Docetaxel (3 arms). Primary endpoints: Objective Response Rate (ORR), Number of participants who experience one or more adverse events (AEs) and 1 more. Planned start Aug 2025; status: authorised.
02
Drugs
ifinatamab deruxtecanraludotatug deruxtecandocetaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2024-518839-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518839-11-00.